MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
- As of September 30, 2022, cash and cash equivalents were EUR
- Revenues of EUR 0.4 million1 in Q3 2022
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French
clinical-stage biotech and a pioneer in the development of
Microbiome Ecosystem TherapiesTM (MET) dedicated to improving
survival outcomes for patients with cancer, today reported its
cash position as of September 30, 2022, and its revenues for the
third quarter of 2022.
As of September 30, 2022, total cash and cash equivalents were
EUR 40.3 million, as compared to EUR 38.4 million as of June 30,
2022, and EUR 43.3 million as of December 31, 2021. The net
increase in cash over the third quarter of 2022 was EUR 1.9
million. This increase reflects:
- Net financing inflows from receipt of funds of EUR 4.3 million
in bank loans from CIC and Bpifrance. - Receipt of the
R&D tax credit related to R&D expenditure for the full year
2021, totaling EUR 2.0 million - Financing of operations and
ongoing development programs of EUR 4.4 million.
Revenues in Q3 20221
MaaT Pharma reported revenues2 from its compassionate access
program of EUR 0.4 million for the quarter ended September 30,
2022, and year to date revenues of EUR 0.9 million compared to EUR
0.2 million for same quarter in 2021 and EUR 0.6 million for the
9-months ended September 30, 2021.
Third quarter clinical and operational highlights
MaaT013, the lead MET drug candidate for hospital use in an
- Phase 3 open label, single arm trial (ARES) for the treatment
of acute Graft-versus-Host Disease: in Q3 2022, in addition to
France, Germany, Spain, Austria where the trial is ongoing, the
Company received regulatory approvals in Belgium. An interim review
of preliminary data after enrollment of half of the patients in the
study is expected in the first half of 2023.
- Randomized, placebo-controlled proof-of-concept Phase 2a trial
(PICASSO), sponsored by AP-HP3, evaluating MaaT013 in combination
with immune checkpoint inhibitors for patients with metastatic
melanoma, is ongoing. A first internal data review focusing on
safety and some biomarker data is expected in the first half of
- In the US, interactions with the U.S. Food and Drug
Administration (FDA) remain active regarding MaaT013, for which US
development is currently on clinical hold following an FDA
communication received in August 2022 requiring additional
information on the safety and efficacy of the Company’s “pooling”
- Pursuit of the Early Access Program in Europe in place since
2021 allowing patients to benefit from early access to the MaaT013
therapy, mainly for the treatment of acute Graft-vs-host-Disease.
As of today, the Company has safely treated over 160 patients with
MaaT013 in Europe.
- On November 3, 2022, MaaT Pharma announced the release of an
abstract, which was selected for an oral presentation at the
American Society of Hematology (ASH) 2022 Annual Meeting from
December 10-13 in New-Orleans, Louisiana, U.S.A. The oral
presentation will occur on December 10, 2022; 10:15am EST and will
detail consolidated results from 81 patients with
steroid-resistant, gastrointestinal, acute
Graft-versus-Host-Disease (GI-aGvHD) treated with MaaT013 as
salvage therapy, as part of the ongoing Early Access Program
(EAP). Link to abstract here.
MaaT033, the Company’s first MET for oral administration as
adjunctive and maintenance treatment for patients receiving
allogeneic hematopoietic stem cell transplantation (allo-HSCT):
- Preparations are ongoing for a pivotal Phase 2b trial to
evaluate MaaT033’s safety and efficacy in improving overall
survival and preventing complications in patients with blood
cancers receiving allo-HSCT; based on current plans, the Company
expects to initiate the study in Q4 2022.
- On November 3rd, 2022, MaaT Pharma announced the release of an
abstract, which was selected for a poster presentation at the
American Society of Hematology (ASH) 2022 Annual Meeting. Poster
presentation will occur on December 11, 2022: 6:00pm - 8:00pm EST
and will present detailed results from the Phase 1b clinical trial
(CIMON) of MaaT033 in patients with acute myeloid leukemia.
Link to abstract here.
- On October 4th, 2022, MaaT Pharma appointed Dr. Nathalie
Corvaïa as Chief Scientific Officer to oversee the Company’s
non-clinical R&D strategies and its proprietary, AI-based MET
drug design and development platform, gutPrint®.
Upcoming scientific conferences participation
- November 8-10, 2022 – 9th International Human Microbiome
Consortium (IHMC) Congress – Kobe, Japan:Hervé Affagard, CEO
and cofounder of MaaT Pharma, and Dr. Aurore Duquenoy, R&D
specialist at MaaT Pharma will present three scientific posters at
the conference. Link to the Congress here.
- November 9-11, 2022 – 21st Société Francophone de Greffe de
Moelle et de Thérapie Cellulaire (SFGM-TC) Congress – Booth #10 –
Bordeaux, France: Dr. Emilie Plantamura, Head of Clinical
Development at MaaT Pharma and Claire de Condé, Head of Clinical
Operations at MaaT Pharma, and Mélanie Tilte, Clinical Project
Manager at MaaT Pharma will attend the congress and will be
available for discussions at MaaT Pharma’s booth #10.
Link to the event here.
Upcoming investor conferences participation
- November 14, 2022 – 7th annual conference LSX Inv€$tival
Showcase – London, UK: Siân Crouzet, Chief Financial Officer of
MaaT Pharma and Dr. Carole Schwintner, Chief Technology Officer of
MaaT Pharma will attend the investor event and participate in the
European Lifestar Awards, where MaaT Pharma is a finalist for the
IPO of the year category. Additional information available on
the LSX website here.
- November 15-17, 2022 – 13th Annual Jefferies London
Healthcare Conference – London, UK: Siân Crouzet, Chief
Financial Officer of MaaT Pharma and Dr. Carole Schwintner, Chief
Technology Officer of MaaT Pharma will attend the conference.
- November 21, 2022 – Kepler Cheuvreux Life Sciences Day
– Digital: Hervé Affagard, CEO and cofounder of MaaT Pharma
will attend the event.
- November 29, 2022 – Investir day – Paris, France: Siân
Crouzet, Chief Financial Officer of MaaT Pharma and Dr. Savita
Bernal, Chief Business Officer of MaaT Pharma will attend the
investor event. Additional information available on the
dedicated website here.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, a Phase 3 clinical trial for patients with acute GvHD,
following the achievement of its proof of concept in a Phase 2
trial. Its powerful discovery and analysis platform, gutPrint®,
supports the development and expansion of its pipeline by
determining novel disease targets, evaluating drug candidates, and
identifying biomarkers for microbiome-related conditions.
The company’s Microbiome Ecosystem Therapies are produced
through a standardized cGMP manufacturing and quality control
process to safely deliver the full diversity of the microbiome, in
liquid and oral formulations. MaaT Pharma benefits from the
commitment of world-leading scientists and established
relationships with regulators to support the integration of the use
of microbiome therapies in clinical practice.
MaaT Pharma is the first company developing microbiome-based
therapies listed on Euronext Paris (ticker: MAAT).
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
1 Unaudited data 2 Revenues correspond to
compensation invoiced in relation to the compassionate access
program, as approved by the French National Drug Safety Agency
(Agence Nationale de Sécurité du Médicament or ANSM).
3 AP-HP: Assistance Publique - Hôpitaux de Paris
version on businesswire.com: https://www.businesswire.com/news/home/20221108005899/en/
MaaT Pharma - Investor relations Hervé AFFAGARD
Co-Founder and CEO Siân Crouzet, COO/ CFO +33 4 28 29 14 00
MaaT Pharma - media relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 07 55 25 36
Trophic Communications - Corporate and medical
Communications Jacob VERGHESE or Gretchen SCHWEITZER +49 89
2070 89831 email@example.com
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Jan 2023 bis Feb 2023
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Feb 2022 bis Feb 2023